Two-months quality of life of COVID-19 invasively ventilated survivors; an Italian single-center study.

BACKGROUND: COVID-19 disease can lead to severe functional impairments after discharge. We assessed the quality of life of invasively ventilated COVID-19 ARDS survivors.
METHODS: We carried out a prospective follow-up study of the patients admitted to the Intensive Care Units (ICUs) of a teaching hospital. Patients affected by COVID-19 ARDS who required invasive ventilation and were successfully discharged home were assessed through the telephone administration of validated tests. We explored survival, functional outcomes, return to work, quality of life, cognitive and psychological sequelae. The main variables of interest were the following: demographics, severity scores, laboratory values, comorbidities, schooling, working status, treatments received during ICU stay, complications, and psychological, cognitive, functional outcomes.
RESULTS: Out of 116 consecutive invasively ventilated patients, overall survival was 65/116 (56%) with no death occurring after hospital discharge. Forty-two patients were already discharged home with a median follow-up time of 61 (51-71) days after ICU discharge and 39 of them accepted to be interviewed. Only one patient (1/39) experienced cognitive decline. The vast majority of patients reported no difficulty in walking (32/35:82%), self-care (33/39:85%), and usual activities (30/39:78%). All patients were either malnourished (15/39:38%) or at risk for malnutrition (24/39:62%). Exertional dyspnea was present in 20/39 (51%) patients. 19/39 (49%) reported alterations in senses of smell and/or taste either before or after hospitalization.
CONCLUSIONS: Invasively ventilated COVID-19 ARDS survivors have an overall good recovery at a 2-months follow-up which is better than what was previously reported in non-COVID-19 ARDS patients.

In this prospective follow‐up of survivors after severe COVID‐19 ARDS, 39 of 42 patients discharged to their homes were assessed. There was an overall good recovery 2 months after discharge, with reduced body weight and exertional dyspnea being the main complaints.

INTRODUCTION

The Coronavirus Disease 2019 (COVID‐19) pandemic led to a dramatic number of Intensive Care Unit (ICU) admissions. In Italy, as of November 7th, 2020, 902,490 people were diagnosed with SARS‐CoV‐2 infection, and 41,063 died.

COVID‐19 is in most cases a self‐limited lower respiratory tract illness, but in some patients, it may cause acute respiratory distress syndrome (ARDS), shock, and multi‐organ failure. , , Long‐term clinical outcomes of ARDS survivors is a topic of high interest ; over the years, ARDS mortality declined but its incidence increased, and a growing number of ARDS survivors present functional, psychological, and cognitive consequences persisting for years. Long‐term follow‐up of survivors of Severe Acute Respiratory Syndrome (SARS‐CoV‐1) and Middle East Respiratory Syndrome (MERS) showed a high prevalence of post‐traumatic stress disorder (PTSD) (39%), depression (33%), anxiety (30%), and reduced quality of life.

Up to one‐third of general ICU patients develop the so‐called Post‐Intensive Care Syndrome (PICS), which includes cognitive, physical, and psychological sequelae, occurring independently of the reason for ICU admission. PICS leads to significant burden and costs for patients, caregivers, and society. It reduces patients’ quality of life, due to an impaired physical and cognitive functioning and a delay or inability to return to work. Follow‐up ICU of patients can facilitate prompt recognition and treatment of PICS and improve long‐term physical, psychological, and cognitive outcomes.

The short‐term mortality of invasively ventilated COVID‐19 ARDS patients is extremely high, in the range of 80%‐90%, , and the middle‐term outcome and quality of life of survivors is unknown. COVID‐19 is severe and multifactorial, and it involves several organs and systems. In the hypothesis that COVID‐19 disease can lead to severe functional impairments after discharge, the primary aim of this study was to assess the quality of life of invasively ventilated COVID‐19 ARDS survivors.

METHODS

Study design and setting

This study is part of the COVID‐BioB study, an observational investigation performed at San Raffaele Scientific Institute—a 1,350‐bed university hospital in Milan, Italy. The study was approved by the hospital Ethics Committee (protocol No. 34/int/2020) and was registered on ClinicalTrials.gov (NCT04318366). All the authors reviewed the manuscript and vouch for the accuracy and completeness of the data and adherence to the study protocol.

Our hospital was immediately involved in the management of the COVID‐19 surge. Since the beginning, a reorganization of large areas of the hospital took place, in order to admit COVID‐19 patients, and elective surgical activity was rapidly reduced and then stopped. , , The emergency department admitted simultaneously up to 70 patients requiring oxygen therapy or non‐invasive ventilation (NIV). In a few days, we had a total of 279 general ward beds dedicated to COVID‐19 patients; moreover, the ICU beds were also increased from 28 to 72 (54 of them dedicated to critical COVID‐19 patients). Healthcare staff was rapidly trained in order to use personal protective equipment and deliver care to critically ill patients. We were able to have a nurse ratio of at least 1:3 (one nurse for three patients) in our ICUs, therefore, ensuring high standards of care.

Inclusion and exclusion criteria

We included all adult patients with COVID‐19 ARDS admitted to an ICU of San Raffaele Scientific Institute during the study period (February 25th, 2020 – April 27th, 2020), who received at least one day of invasive ventilation, and were already discharged home on June 3rd. Patients aged 18 years or over admitted to an ICU at San Raffaele Scientific Institute, affected by confirmed SARS‐CoV‐2 infection (defined as positive real‐time reverse‐transcriptase polymerase chain reaction from a nasal and/or throat swab together with signs, symptoms, and radiological findings suggestive of COVID‐19 pneumonia), were included in the study.

Patients management

Anesthesiologists and intensivists managed patients in the ICUs, while internal medicine and infectious diseases specialists managed the general wards, supported by intensivists for deteriorating patients.

General ward patients could receive non‐invasive ventilation, usually continuous positive airway pressure (CPAP) and, in selected cases, some were treated with prone positioning while receiving non‐invasive ventilation (NIV). Prone position in the main ward was suggested in case of poor response to NIV, and if the first hour of treatment showed improvement it was continued. , We were fully aware of the theoretical risk of aerosolization during NIV, exposing staff and patients to an increased risk of infection, but during such a pandemic, the number of ICU beds for mechanical ventilation through tracheal intubation could rapidly become insufficient, whereas NIV can be offered also outside the ICU.

A management protocol for patients with COVID‐19 respiratory failure was implemented in our hospital. If the partial pressure of arterial oxygen (PaO2) was less than 8 kPa (60 mm Hg) or saturation of peripheral oxygen (SpO2) was less than 90%, while breathing room air, physicians would increase the fraction of inspired oxygen (FiO2) up to 70‐80% via non‐rebreathing mask with an O2 flow up to 15 L/min, and the target SpO2 would be >94%. If SpO2 was stable above 94%, the indication was to continue the treatment and monitor for deterioration. If SpO2 < 94% despite 15 L/min O2 via nonrebreathing mask, the physicians would start CPAP (initial parameters FiO2 0.5, PEEP 7.5cmH2O), with target SpO2 > 94% and recommended blood gas analysis after 1 hour, with the possibility to increase the PEEP up to 12 cmH2O if SpO2 < 94%. Intubation was considered if SpO2 < 94% and/or PaO2/FiO2 < 26.7 kPa (200 mm Hg) and respiratory rate (RR) > 25‐30 after 1 hour. For mechanically ventilated patients in the ICU, we adopted current recommendations for mechanical ventilation in patients with ARDS.

Data collection

Study methodology has been previously described. We prospectively collected data on medical history, comorbidities, the Simplified Acute Physiology Score II (SAPS II), ARDS severity according to the Berlin Definition, major organ support, and outcome.

To assess mid‐term follow‐up, discharged patients were contacted by phone by a trained investigator after a median of 61 (51‐71) days from ICU discharge. The follow‐up questionnaire is described in detail in the Supplemental Digital Content. Data were progressively recorded in a dedicated database during the phone interview. For this study, we present the follow‐up data as of June 3rd, 2020.

Study outcomes and follow‐up protocol

We evaluated multidimensional outcomes through the phone administration of various tests.

Functional outcomes were explored via the Glasgow Outcome Scale extended (GOSe) which assesses physical recovery and disability, , the Functional Ambulation Classification (FAC) which evaluates the autonomy in walking, the Borg Category Ratio 10 (CR‐10) scale for self‐evaluation of dyspnea , (either at rest and during an effort such as two floors of stairs), and the Mini Nutritional Assessment – Short Form (MNA‐SF) which evaluates nutritional status. Quality of life was assessed through the Euro Quality 5 Dimensions 3 Levels (EQ5D‐3L), , which includes an overall score self‐evaluated by the patient, the Visual Analogue Scale (VAS). Psychological outcomes were evaluated with the Hospital Anxiety and Depression Scale (HADS), , the PTSD Checklist for DSM‐5 (PCL‐5 ‐ which assesses PTSD), , , and the Insomnia Severity Index (ISI). Cognitive status was assessed through the Italian Telephonic version of the Mini‐Mental State Examination (Itel‐MMSE).

We also explored patients’ smoking habit, basal working status and return to work, alterations in senses of smell and taste. We also asked the patients to report any form of discrimination that they (or their families) may have endured because of the disease.

Baseline data of consecutive COVID‐19 patients who died during or after ICU stay were collected as well.

Statistical analysis

Statistical analysis was performed using Stata 16 (StataCorp. 2016. Stata Statistical Software: Release 16. College Station, TX: StataCorp LP). Data were presented as medians with interquartile range (IQR: 25th – 75th percentiles) or as means with standard deviation (SD). Means and SD were used with normally distributed variables, while medians and IQR were used with non‐normally distributed variables. Categorical and dichotomous variables were presented as absolute number and percentages (%). No data imputation for missing data was performed.

RESULTS

Baseline characteristics of patients and ICU course

Among invasively ventilated COVID‐19 ARDS patients admitted to our ICUs in the study period, all the first 42 discharged home were contacted after a median follow‐up of 61 (51‐71) days after ICU discharge (Figure 1): 39 accepted to reply (adherence rate 93%: one patient was abroad; one had a psychiatric illness; and one was confirmed alive by the general practitioner but did not answer).

FIGURE 1

Flowchart

The mean age of our cohort of patients was 56 ± 10.5 years at ICU admission (six were >70 y), and 35 (90%) were males. Twenty‐eight (72%) had a job, two patients (5.1%) were current smokers, and the most frequent comorbidity was hypertension (49%). Mean SAPS II score was 31 ± 8.7, while the PaO2/FiO2 mean ratio was 16.7 ± 8.2 kPa (125 ± 61.8 mm Hg). Patients were on mechanical ventilation for a median of 9 (6‐14) days. At the time of evaluations for the start of mechanical ventilation, according to the Berlin criteria, 15 out of 39 patients were affected by severe ARDS, 18 out of 39 by moderate ARDS, and 4 out of 39 by mild ARDS, with two missing data. Then, during their ICU stay, all but one fulfilled the criteria for severe ARDS. Also, at the time of ICU admission, 38 out of 39 patients were already intubated.

The vast majority of patients required inotropic support (33 patients, 87%), neuromuscular blocking agents (31 patients, 82%), and prone positioning (28 patients, 74%). Two patients (5.3%) received extra‐corporeal membrane oxygenation (ECMO), and three patients (8.1%) received continuous renal replacement therapy.

The median length of ICU stay was 10 (7‐16) days, while the overall hospital stay was 30 (23‐44) days. Overall survival was 65/116 (56%) with no death occurring after hospital discharge; of the 51 patients who died in hospital, 46 died while still in the ICU, and 5 died in the general ward, after ICU discharge.

Characteristics of the patients at baseline and during ICU course are presented in Table 1 and Table S1, and results of mid‐term follow‐up questionnaires are presented in Table 2 and Table 3.

TABLE 1

Characteristics of the 39 invasively ventilated COVID‐19 ARDS ICU patients who were discharged home and replied to the follow‐up questionnaire

Baseline	Value	Missing data
Age (years), mean ± SD	56 ± 10.5	‐
Male sex, no. (%)	35 (90%)	‐
BMI (kg∙m‐2), mean ± SD	29 ± 5.1	11
SAPS II (points)	31 ± 8.7	2
PaO2/FiO2 at ICU admission, mean ± SD (kPa)	16.7 ± 8.2	2
(mmHg)	125 ± 61.8
ARDS severity at evaluation (according to Berlin criteria)		2
‐ Mild, no. (%) ‐ Moderate, no. (%) ‐ Severe, no. (%)	4 (11%) 18 (48%) 15 (40%)
Comorbidities		‐
‐ 0, no. (%)	18 (46%)
‐ 1, no. (%)	16 (41%)
‐ 2, no. (%)	4 (10%)
‐ >3, no. (%)	1 (2.6%)
Schooling		2
‐ Primary school, no. (%)	4 (11%)
‐ Middle school, no. (%)	12 (32%)
‐ High school, no. (%)	14 (38%)
‐ Bachelor's Degree, no. (%)	3 (8.1%)
‐ Master's Degree, no. (%)	4 (11%)
Working status		‐
‐ working, no. (%)	28 (72%)
‐ unemployed or retired, no. (%)	11 (28%)
Smoking status		‐
‐ Never, no. (%)	17 (44%)
‐ Current smoker, no. (%)	2 (5.1%)
‐ Former smoker > 1 month, no. (%)	20 (51%)
During ICU stay
Worst grade of ARDS severity (according to Berlin criteria)		1
‐ Mild, no. (0%)	‐
‐ Moderate, no. (0%)	‐
‐ Severe, no. (0%)	38 (100%)
CRRT, no. (%)	3 (8.1%)	2
Tracheostomy, no. (%)	7 (18%)	‐
Prone positioning, no. (%)	28 (74%)	1
Inotropic support/vasopressors, no. (%)	33 (87%)	1
Pneumothorax, no. (%)	3 (7.9%)	1
ECMO, no. (%)	2 (5.3%)	1
Neuromuscular Blocking agents, no. (%)	31 (82%)	1
Days in hospital before ICU admission, median (IQR)	1 (0‐4)	‐
Length of ICU stay, median (IQR)	10 (7‐16)	‐
Length of Overall hospital stay, median (IQR)	30 (23‐44)	‐
Days from ICU discharge to follow‐up, median (IQR)	61 (51‐71)	‐

ARDS, acute respiratory distress syndrome; COVID‐19, coronavirus disease 2019; ICU, intensive care unit; SD, standard deviation; BMI, body mass index; SAPS II, simplified acute physiology score II; PaO2, partial pressure of arterial oxygen; FiO2, fraction of inspired oxygen; CRRT, continuous renal replacement therapy; ECMO, extra‐corporeal membrane Oxygenation; IQR, interquartile range; FU, follow‐up.

Percentage may not total 100 because of rounding.

TABLE 2

Quality of life, psychological, cognitive, and miscellaneous outcomes of 39 invasively ventilated COVID‐19 ARDS ICU patients already discharged home

Items	Value	Missing data
Euro Quality 5 Dimensions 3 Levels (EQ5D3L) ‐mobility		‐
‐ No difficulty to walk, no. (%)	32 (82%)
‐ Moderate difficulty to walk, no. (%)	6 (15%)
‐ Unable to walk, no. (%)	1 (2.6%)
Euro Quality 5 Dimensions 3 Levels (EQ5D3L) – self‐care		‐
‐ No difficulty to wash or dress, no. (%)	33 (85%)
‐ Moderate difficulty to wash or dress, no. (%)	6 (15%)
Euro Quality 5 Dimensions 3 Levels (EQ5D3L) – usual activities		‐
‐ No difficulties in usual activities, no. (%)	30 (78%)
‐ Moderate difficulties in usual activities, no. (%)	8 (20%)
‐ Not able in usual activities, no. (%)	1 (2.6%)
Euro Quality 5 Dimensions 3 Levels (EQ5D3L) – pain or discomfort		‐
‐ No pain or discomfort, no. (%)	21 (54%)
‐ Light pain/discomfort, no. (%)	2 (5.1%)
‐ Moderate pain/discomfort, no. (%)	16 (41%)
Euro Quality 5 Dimensions 3 Levels (EQ5D3L) – anxiety and depression		‐
‐ Not anxious/depressed, no. (%)	31 (79%)
‐ Moderately anxious/depressed, no. (%)	8 (21%)
‐ Severely anxious/depressed, no. (%)	0 (0%)
Visual Analogue Scale (VAS) for self‐perceived health state, mean ± SD	74 ± 16	‐
Hospital Anxiety and Depression Scale (HADS) – anxiety, median (IQR)	2 (0‐3)	2
Hospital Anxiety and Depression Scale (HADS) – depression, median (IQR)	1 (0‐3)	2
Post‐Traumatic Stress Disorder Checklist for DSM‐5 (PCL‐5), median (IQR)	7 (4‐16)	2
Insomnia Severity Index (ISI), median (IQR)	1 (0‐5)	1
Italian telephone Mini Mental State Examination (I‐tel MMSE), median (IQR)	22 (21‐22)	2
Working status		‐
‐ Back to previous job, no. (%)	8 (21%)
‐ Previously unemployed or retired, no. (%)	11 (28%)
‐ Working with different tasks due to disease, no. (%)	1 (2.6%)
‐ Not working for disease DEPENDENT reasons, no. (%)	19 (49%)
Alteration in smell Before ICU, no. (%)	6 (15%)	‐
Persisting after Hospital discharge, no. (%)	5 (13%)	‐
Alteration in taste Before ICU, no. (%)	12 (31%)	‐
Persisting after Hospital discharge, no. (%)	8 (21%)	‐
Discrimination due to the disease – Personal – at least one episode, no (%)	3 (7.7%)	‐
None, no. (%)	36 (92%)	‐
Discrimination due to the disease – Family – at least one episode, no. (%)	2 (5.1%)	‐
None, no. (%)	37 (95%)	‐
Denied access to non‐urgent care, no. (%)	0 (0%)	‐

ARDS, acute respiratory distress syndrome; COVID‐19, coronavirus disease 2019; ICU, intensive care unit; SD, standard deviation; IQR, interquartile range.

Percentage may not total 100 because of rounding.

TABLE 3

Functional outcomes of 39 invasively ventilated COVID‐19 ARDS ICU patients already discharged home

Items	Value	Missing data
Glasgow Outcome Scale extended (GOSe)		‐
‐ Upper good recovery, no. (%)	10 (26%)
‐ Lower good recovery, no. (%)	16 (41%)
‐ Upper Moderate Disability, no. (%)	7 (18%)
‐ Lower Moderate Disability, no. (%)	5 (13%)
‐ Upper Severe Disability, no. (%)	1 (2.6%)
‐ Lower severe disability, no. (%)	0 (0.0%)
Dyspnea at rest (Borg Category Ratio 10 scale)		‐
‐ Nothing at all, no. (%)	38 (97%)
‐ Light, no. (%)	1 (2.6%)
Exertional Dyspnea (Borg Category Ratio 10 scale)		‐
‐ Nothing at all, no. (%)	19 (49%)
‐ Very light, no. (%)	1 (2.6%)
‐ Light, no. (%)	4 (10%)
‐ Moderate, no. (%)	10 (26%)
‐ Intense, no. (%)	3 (7.7%)
‐ Strong, no. (%)	1 (2.6%)
‐ Very strong, no. (%)	1 (2.6%)
Mini Nutritional Assessment – Short Form (MNA‐SF)		‐
‐ 0‐7 points (malnourished), no. (%)	15 (38%)
‐ 8‐11 points (at risk for malnutrition), no. (%)	24 (62%)
‐ 12‐14 points (normal nutritional state), no. (%)	0 (0%)
Functional Ambulation Classification (FAC)		‐
‐ Can walk independently anywhere, no. (%)	32 (82%)
‐ Requires help on stairs, slopes or uneven surfaces, no. (%)	4 (10%)
‐ Verbal supervision or standby help, no. (%)	1 (2.6%)
‐ Need continuous or intermittent support, no. (%)	2 (5.1%)

ARDS, acute respiratory distress syndrome; COVID‐19, coronavirus disease 2019; ICU, intensive care unit.

Percentage may not total 100 because of rounding.

Cognitive outcomes

After a median of 61 (51‐71) days after ICU discharge, only one patient (2.6%) had cognitive impairment at the Itel‐MMSE scale.

Quality of life

The overall quality of life explored through the administration of the EQ5D‐3L test showed no difficulty in walking (32/39:82%), self‐care (33/39:85%), and usual activities (30/39:78%), with only eight (21%) patients reporting moderate anxiety or depression.

Psychological outcomes

Psychological tests confirmed low rates of anxiety, depression, PTSD, and insomnia.

Working status

Before the onset of the disease, 28 out of 39 patients (72%) were working. At 2 months after discharge, despite a good recovery, only eight patients (21%) had returned to their usual job, while one patient (2.6%) returned with different tasks due to the disease. Eleven out of 39 patients (28%) were unemployed or retired as before the COVID‐19 disease, but 19 patients (49%) were not working because of COVID‐19 disease‐dependent reasons.

Other outcomes

When investigating the subjective perception of patients and relatives after the discharge, asking if they ever felt discriminated in any field of their life because of the disease, upon returning to their everyday life, very few patients reported personal (3/39:7.7%) or family (2/39:5.1%) discrimination, in their everyday life, due to their COVID‐19 illness. No patient reported a lack of access to non‐urgent care (ie, outpatient clinics) because of the disease.

A total of 6 out of 39 patients (15%) reported alterations in smell before the disease, and only in one of them, this situation persisted after hospital discharge. Four further patients reported alterations in smell only after hospital discharge. Alteration in taste was reported by 12 out of 39 patients (31%) before the disease, and in 3 patients this situation persisted after hospital discharge. Five further patients reported alteration in taste only after hospital discharge. Overall, 19/39 (49%) reported either alteration in senses of smell or taste either before or after hospitalization.

Functional outcomes

67% of patients (26 out of 39) reported good recovery, according to the GOSe. Only one patient (2.6%) complained about dyspnea at rest, while almost half of the patients (20 out of 39) reported exertional dyspnea (varying from “very light” to “very strong”). We found a good level of autonomy in walking (82% of the patients—32 out of 39—could walk independently anywhere). The mean nutritional status, explored with the MNA‐SF, showed that 15 patients (38%) were malnourished and 34 (62%) at risk for malnutrition.

DISCUSSION

Key findings

This report of outcomes and quality of life of invasively ventilated COVID‐19 ARDS survivors shows that, at a median follow‐up of 2 months, overall survival was 56% with no death occurring after hospital discharge. The vast majority of patients reported no cognitive decline, no limitation in daily activities, and no psychological impairment or PTSD. On the other side, all patients were at least at risk for malnutrition and half of them had exertional dyspnea.

Relationship to previous studies

Only two studies investigated the quality of life of COVID‐19 ICU patients so far, and the majority of them focused on the need for a post‐ICU follow‐up of COVID‐19 critical patients, due to the well‐known PICS. , , ,

Valent A. et al, explored the health‐related quality of life (HRQOL) of COVID‐19 ICU French survivors at a 3 months evaluation: 89% of patients described pain or discomfort; 47% worsened mobility; 42% worsened usual activities; 42% worsened anxiety/depression; and 10% worsened self‐care. These results are different from those reported by our study: 45% of our patients experienced pain or discomfort to some extent; 18% worsened mobility; 22% worsened usual activities; 21% anxiety/depression; and 15% worsened self‐care. This difference might be explained by a different follow‐up period, and by small study populations. Moreover, different ICU managements (eg, neuromuscular blocking, inotropic support) can modify HRQOL scores.

Garrigues E. et al explored post‐discharge persistent symptoms and HRQOL in another cohort of COVID‐19 French patients. They compared patients managed in hospital wards without need for intensive care, with those who were transferred to the ICU, and found that most patients requiring hospitalization for COVID‐19 still have persistent symptoms, especially fatigue and dyspnea. They also found that HRQOL was quite satisfactory, and except for pain and discomfort, there was no significant difference regarding persistent symptoms and HRQOL between ward and ICU patients. These findings are not comparable with ours since only 14 patients were mechanically ventilated among the ICU patients, and their outcomes were grouped together with patients admitted to ICU who only required NIV, while all our patients required invasive mechanical ventilation.

Our patients were relatively young, a vast majority were males and overweight with few comorbidities, consistent with literature data reported so far. We found that the number of active smokers was extremely low. This finding is surprising and counterintuitive. We had already noticed this finding when presenting the short‐term outcome of our patients, , but at that time there was the possibility of poor medical history recording during the pandemic outbreak. Nonetheless, the protective effect of active smoking on the progression toward severe COVID‐19 disease has now been confirmed by several publications in high‐impact journals which have recently been systematically reviewed.

Previous studies assessed long‐term sequelae of similar coronavirus diseases (MERS and SARS). These studies collectively showed a high prevalence of post‐traumatic stress disorder (PTSD) (39%), depression (33%), anxiety (30%), and reduced quality of life. Previous studies on general ICU population and non‐COVID‐19 ARDS , patients also showed that at least one‐third of patients are affected by PTSD. The difference with our study could be explained by a different baseline severity or a different length of follow‐up. In fact, patients could show a delayed onset of psychological disorders, as reported in previous studies. ,

Interestingly, although patients reported a good recovery, few of them returned to work. This is consistent with what has been previously reported for non‐COVID‐19 ARDS. , Indeed, previous data showed that it can take up to 5 years for critical patients to get back to their previous work. In these terms, our data show that COVID‐19 ARDS is not different from other types of critical illness.

Of note, our mid‐term mortality was 44%. This is in the lower range of short‐term mortality data from other groups in February‐March 2020, , but far more encouraging when compared to early reports of short‐term mortality which was in the range of 80%‐90% for invasively ventilated patients with COVID‐19 ARDS. , Interestingly, mortality in our cohort was higher‐than‐expected as calculated by the SAPS II score, but in line with ARDS predicted mortality based on PaO2/FiO2 ratio.

ICU triage is challenging and controversial during pandemics, when demand exceeds resources. A “first come, first served” basis could possibly be not the best choice while dealing with a pandemic surge. The Society of Critical Care Medicine stated that “The foremost consideration in triage decisions is the expected outcome of the patient in terms of survival and function, which turns on the medical status of the patient. In general, patients with good prognoses for recovery have priority over patients with poor prognoses.” More recently, a triage consensus statement unanimously agreed on the need for explicit guidelines that would facilitate the fair use of scarce resources and the importance of triage guidelines.

Literature data regarding COVID‐19 critical patients receiving invasive mechanical ventilation confirmed that the elderly have poor outcomes: a recent systematic review and meta‐analysis of 57,420 adult patients in 69 studies, reported a case fatality rate greater than 70% among patients aged above 60 years of age. Data from our group, although preliminary, confirmed that age is a strong predictor of survival in COVID‐19 ARDS critical patients. Attempts have been made to develop objective triage scores, but none is currently being used. Therefore, during the pandemic surge, patients were declared eligible or non‐eligible for intubation for age and/or comorbidities by expert intensive care physicians’ collegial evaluation.

Significance of study findings and what this study adds to our knowledge

Due to improvement in short‐term survival, there is now increasing awareness toward long‐term sequelae of critical illness survivors. Ensuring good long‐term quality of life, rather than simply survive an acute event, is now becoming the major goal of intensive care medicine. Our findings are important to raise awareness about the need for follow‐up of COVID‐19 ICU patients, being SARS‐CoV‐2 a novel and still little‐known disease. For this reason, our Hospital set up a multidisciplinary COVID‐19 follow‐up outpatient clinic that was operative since the beginning of April, and in 2 months (April 7th – June 5th), 453 patients were evaluated. The aim of the follow‐up clinic is to identify and address the clinical needs of COVID‐19 survivors. From 2016, our hospital also offers a Post‐ICU Outpatient Clinic, conducted by an intensivist, an ICU nurse, and a psychologist, with the aim to identify patients affected or at risk for PICS. This outpatient clinic was interrupted during the first phase of the pandemic, since all the intensivists were involved in the acute care of patients, but it started again in July 2020 and COVID‐19 ICU survivors are offered the possibility to participate. Furthermore, our data, although exploratory, will be of help to provide baseline data in order to plan future studies on the long‐term outcome of COVID‐19 ARDS. Importantly, our data suggest that, despite disease severity, COVID‐19 ARDS is associated with a high probability of long‐term physical and psychological recovery, if the patient survives the acute illness.

Strengths and limitations of the study

The strengths of our study are the well‐defined and detailed characterization of the cohort of COVID‐19 survivors and our high‐rate of response to follow‐up. Even for the three patients that did not complete the interview, we were able to assess survival status by other strategies. We had very few missing data in the questionnaire, mainly due to language issues (2 patients were foreigners, although Italian speaking) in the administration of slightly more complex tests (HADS, PCL‐5, ISI, Itel‐MMSE). Outcomes are deeply influenced by age and frailty as testified by the baseline data of the first 39 invasively ventilated COVID‐19 ARDS ICU patients who died (Table S1).

A limitation of the study is the limited sample size and the short follow‐up time. Moreover, it is proved that the depth of patient's insights is strongly influenced by means of communication: questionnaires administered by telephone do not have the same degree of reliability as tests administered face to face. Another limitation is the different rehabilitation interventions received by patients, which may influence the reported outcomes. All patients were offered a period of rehabilitation, and almost all had an in‐hospital rehabilitation, while very few were the ones that showed a level of recovery good enough to be discharged home immediately after their general ward stay. Our data are limited to ICU survivors from a single‐center, and may not be generalizable to all COVID‐19 patients.

Future studies and prospects

In consideration of the exercise limitations reported by our patients, future studies should involve objective measures of pulmonary functioning through the administration of tests such as the 6‐minutes walking test (6MWT), Spirometry, and CT‐scan. Also, the role of current or previous smoking in the course of the disease should be addressed in the future. Pain is a field that should be as well adequately explored: nearly 50% of our COVID‐19 ARDS survivors report pain to some extent, and further studies should investigate its quality and characteristics.

CONCLUSION

In summary, in a cohort of consecutive COVID‐19 invasively ventilated ARDS patients we found a 56% survival rate at 2 months after ICU discharge. The overall quality of life in survivors was good, and cognitive and psychological outcomes showed no impairment at the 2 months follow‐up, suggesting that recovery in COVID‐19 patients with ARDS could be better than previously published in non‐COVID‐19 patients.

CONFLICTS OF INTEREST AND SOURCE OF FUNDING

All the authors have disclosed that they do NOT have any conflicts of interest or source of funding.

Supplementary Material

Click here for additional data file.